On Thursday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.5 which represents a slight increase of $0.09 or 0.15% from the prior close of $58.41. The stock opened at ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...

Analyst Price Forecast Suggests 9.53% Downside As of ... The firm decreased its portfolio allocation in BMY by 91.87% over ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

From these selections, we ranked each stock based on the total number of hedge fund ... On September 29, BMO Capital raised ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Bristol Myers is expected to ...

Bristol Myers Squibb Company BMY touched a 52-week high of $56.8 on Nov. 6. The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months ...